Yee, AndrewRaje, Noopur2018-06-272018Yee, Andrew J., and Noopur S. Raje. 2018. “Panobinostat and Multiple Myeloma in 2018.” The Oncologist 23 (5): 516-517. doi:10.1634/theoncologist.2017-0644. http://dx.doi.org/10.1634/theoncologist.2017-0644.http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160277FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class.en-USJournal Article2018-06-2710.1634/theoncologist.2017-0644